Market Newsdesk

SAN JOSE, Calif., April 7, 2021 /PRNewswire/ — Extreme Networks, Inc. (Nasdaq: EXTR) today announced that one of the largest healthcare providers in the Netherlands, Cordaan, has deployed its clinical-grade, cloud-driven networking solutions to optimize operating efficiency, bolster security, and meet increased connectivity demands from people and connected medical devices. With Extreme’s industry leading cloud-driven technology in place, Cordaan can easily scale its network to support bandwidth intensive applications and keep personal and medical IoT devices running safely and securely across 120 locations.

Cordaan provides healthcare to approximately 20,000 citizens in Amsterdam, Diemen, Huizen, and Nieuw-Vennep. The company’s 6,000 employees and 2,500 volunteers offer a range of healthcare services in homes and managed healthcare facilities to help elderly residents, as well as children and adults with learning disabilities and mental health issues.

Key Benefits:

• Scalable connectivity: Purpose-built for today’s distributed enterprise, ExtremeWireless™ Wi-Fi 6 cloud-managed access points and ExtremeSwitching™ technology, including the ExtremeSwitching™ 5520 universal platform, are deployed throughout Cordaan’s network, ensuring secure, scalable connectivity for staff, patients, and visitors wherever they are located. Vulnerability and attack risks are eliminated as Extreme access points offer dedicated, dual-band sensor scans for rogue devices. As the hospital footprint expands and more users, applications, and IoT medical devices are added to the network, Cordaan will be well prepared to meet future needs.

• Seamless and secure cloud network management: The ExtremeCloud™ IQ network management platform provides Cordaan with end-to-end visibility and unlimited access to data, enabling its IT team to monitor and manage devices and services across its distributed network without the need to travel across the country to individual sites. The healthcare provider can also harness the power of network segmentation to quickly spin-up secure Wi-Fi access for patients and staff as needed, separating critical applications and medical devices to protect them in the event of potential cyberattacks and breaches. Further, Cordaan can now leverage open-standard APIs on its network to guide desired business intelligence and workflow decisions.

• Simplified network maintenance and optimized costs: With Extreme Fabric Connect™, upgrading and adding new devices and services to Cordaan’s distributed network is now automated. This reduces reliance on IT specialists to run, maintain, and troubleshoot the network. Further, Cordaan’s IT team has the flexibility to choose and change the appropriate OS for its 5520 universal platforms based on business needs, and can activate changes via automated, zero-touch deployment using ExtremeCloud IQ. The improved level of operating efficiency enables Cordaan’s IT staff to spend more time on new initiatives to improve the patient experience.

Executive Perspectives

Rob Bergfeld, Managed ICT Services, Cordaan

“Everything we do at Cordaan is focused on giving our patients the most comfortable experience as well as the most advanced treatments and care. As our network is central to achieving this, we needed a secure, agile, and resilient cloud-based infrastructure to cope with increased demand from thousands of personal and medical devices so our visitors and staff can continue to experience reliable connectivity. Thanks to Extreme’s cloud-driven network technology, our visitors can stay better connected while our team confidently carries out the critical work of caring for and assisting our patients.”

Henk Bretveld, Country Manager BENELUX, Extreme Networks

“IT is the unseen backbone of any great healthcare organization. Throughout the pandemic, we have seen just how critical a secure, clinical-grade network is to support the users, applications, and devices needed to keep us all healthy. By deploying the ExtremeCloud IQ management platform and cloud-driven networking technologies across hundreds of locations in the Netherlands, Cordaan can guarantee its staff has the tools and technologies in place to meet patient needs and provide the best possible care.”

Additional Resources

• Top Considerations for your Healthcare Cloud Networking Strategy Blog
• Why Health IT Teams Need Cloud Management Now More Than Ever Blog
• Cloud Managed Networking for Dummies eBook
• Omdia 2020 Cloud Managed Networking Report

About Extreme Networks
Extreme Networks, Inc. (EXTR) creates effortless networking experiences that enable all of us to advance. We push the boundaries of technology leveraging the powers of machine learning, artificial intelligence, analytics, and automation. Over 50,000 customers globally trust our end-to-end, cloud-driven networking solutions and rely on our top-rated services and support to accelerate their digital transformation efforts and deliver progress like never before. For more information, visit Extreme’s website at https://www.extremenetworks.com/ or follow us on LinkedIn, YouTube, Twitter, Facebook, or Instagram.

Extreme Networks, the Extreme Networks logo, ExtremeCloud, ExtremeSwitching, ExtremeWireless and Extreme Fabric Connect are trademarks or registered trademarks of Extreme Networks, Inc. in the United States and other countries. Other trademarks shown herein are the property of their respective owners.

View original content to download multimedia:http://www.prnewswire.com/news-releases/dutch-healthcare-provider-cordaan-gains-operating-efficiency-and-security-with-extreme-networks-301263755.html

SOURCE Extreme Networks, Inc.

TEL AVIV, Israel, April 6, 2021 /PRNewswire/ — Innoviz Technologies Ltd. (Nasdaq: INVZ), a technology leader of high-performance, solid-state LiDAR sensors and perception software, announced today that it has appointed Amichai Steimberg, Aharon Aharon, Dan Falk, Ronit Maor, Orit Stav and James Sheridan to its board of directors effective today. They join existing board members Omer Keilaf, Co-Founder and CEO of Innoviz, and Oren Rosenzweig, Co-Founder and Chief Business Officer of Innoviz. The new appointees bring decades of experience leading publicly traded companies in the technology and automotive sectors as executive officers and members of boards of directors.

These appointments follow the consummation of Innoviz’s merger with Collective Growth Corporation (formerly Nasdaq: CGRO) on April 5, 2021.

The following provides information about the new appointees to Innoviz’s board of directors:

• Chairman of the Board: Amichai Steimberg, Former CEO of Orbotech Ltd.
  Mr. Steimberg previously served as President and Chief Operating Officer of Orbotech Ltd. from 2013 to 2019, and as Chief Executive Officer of Orbotech Ltd. from 2019 to 2020. Mr. Steimberg is the President and Chief Operating Officer of Israel Amplify Program Corp., and serves as a board member in several private companies, including as Chairman of the Board of Directors at Airovation Technologies Ltd. From September 2020 to January 2021, Mr. Steimberg served as Chairman of the Board of Directors of Highcon System Ltd., an Israeli company listed on the Tel Aviv Stock Exchange. Mr. Steimberg holds a BSc in Agricultural Economics and Business Administration from the Hebrew University in Jerusalem.

• 
  Aharon Aharon, CEO of Israel Innovation Authority
  Since 2017, Mr. Aharon has served as the Chief Executive Officer of the Israel Innovation Authority, an independent public entity that promotes Israel’s innovation ecosystem. Prior to that, Mr. Aharon served as the Corporate Vice President of Hardware Technologies and General Manager of Apple Israel from 2011 to 2017, and as the CEO of Camero from 2004 to 2010 (at which time the company was acquired). Mr. Aharon served as Chairman of the Board of Directors at Discretix Technologies from 2003 to 2010 (the company was subsequently acquired by ARM in 2014) and as COO at Zoran, a NASDAQ traded company from 1996 to 2001. Mr. Aharon holds a B.Sc in Computer Engineering and a M.Sc in Electrical Engineering from the Israel Institute of Technology.

• 
  Ronit Maor, Chief Financial Officer of Earnix Inc.
  Since 2017, Ms. Maor has served as the Chief Financial Officer of Earnix Inc., a leading SaaS company providing an AI-driven pricing, rating and product personalization for insurance and banking customers. Prior to joining Earnix Inc., Ms. Maor was the Chief Financial Officer at Pontis, a leading digital customer engagement company, from 2012 until its acquisition by Amdocs in 2016. Ms. Maor holds a BSc in Industrial Engineering and Management from the Tel Aviv University.

• 
  Dan Falk, Board Member at Nice Ltd. and Ormat Technologies Inc.
  Mr. Falk has served as a member of the board of directors of Nice Ltd., a Nasdaq-listed company, since 2001, and has served as a member of the board of directors of Ormat Technologies Inc., a New York Stock Exchange-listed company, since 2004. From 1999 to 2000, Mr. Falk was President and Chief Operating Officer of Sapiens International Corporation N.V. From 1985 to 1999, Mr. Falk served in various positions in Orbotech Ltd., the last of which were Chief Financial Officer and Executive Vice President. Mr. Falk was also a member of the Board of Directors of Orbotech Ltd. Mr. Falk holds a Bachelor’s degree in Economics and Political Science and a Master’s degree in Business Administration from the Hebrew University in Jerusalem.

• 
  Orit Stav, Seasoned Investment Manager
  Ms. Stav is a seasoned investment manager with 20 years of experience in the Technology, Venture Capital, and Private Equity sectors. She currently serves as a member of the board of directors of Camtek Ltd., Doral Renewable Energy Resources Ltd., Hadasit Bio-holdings Ltd., YSB Group, HomeBioGaz, A.Luzon Real Estate and Finance Ltd. and ORT Technologies Ltd. Since 2015, Ms. Stav has served as a Managing Partner at Israel Innovation Partners. Prior to that, she helped lead investments in companies such as Siemens Venture Capital and Eva Ventures. Ms. Stav holds a Master of Business Administration from Hertfordshire University, UK, and a Bachelor’s degree in Arts (Economics and Management) from the Tel Aviv University.

• 
  James Sheridan, CEO of Perception Capital Partners, SPAC Sponsor
  Mr. Sheridan is a senior operating executive with over 25 years of experience and deep experience in the automotive industry. He has experience as both an operating executive (Chief Procurement Officer) and as a leader of the Purchasing Practice at McKinsey. His prior experiences include roles as CPO at Forterra, Senior Expert at McKinsey, CPO at Champion, and a variety of roles with Ford Motor Company. Mr. Sheridan holds a B.A. from the College of the Holy Cross and M.B.A from Carnegie Mellon.

“We are thankful to have assembled an incredible collection of experts to serve on Innoviz’s board as we navigate through this next stage of growth,” said Omer Keilaf, Co-Founder and CEO of Innoviz. “Our team has worked diligently to identify leaders in the technology and automotive spaces who are uniquely positioned to facilitate our transition to a public company and drive shareholder value in the process. We are looking forward to working with this accomplished group and leveraging their expertise as we continue to push the boundaries of LiDAR and enter high volume series production.”

Amichai Steimberg, future Chairman of the Board, commented: “Innoviz has quickly earned its reputation as a global leader in high performance, automotive-grade LiDAR. Innoviz is pushing the autonomous vehicle industry forward in innovative ways. I am confident this group of leaders will successfully oversee the deployment of Innoviz’s LiDAR and perception software to BMW and other leading vehicle manufacturers in the near term.”

About Innoviz Technologies
Innoviz is a leading provider of technology that will put autonomous vehicles on roads, ultimately changing the world and making life better. Innoviz is the only company with LiDAR technology that can “see” better than a human driver, while also meeting the automotive industry’s strict requirements for performance, safety and price. Selected by BMW for its fully electric iX autonomous car program, Innoviz’s technology will be the first to be deployed in consumer vehicles. Innoviz is backed by top-tier strategic partners and investors, including SoftBank Ventures Asia, Samsung, Magna International, Aptiv, Magma Venture Partners, and others. For more information, visit www.innoviz.tech.

Forward Looking Statements
This announcement contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the benefits of the transaction, the services offered by Innoviz and the markets in which it operates, and Innoviz’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this announcement, including but not limited to, the ability to implement business plans, forecasts, and other expectations following the transaction, the ability to identify and realize additional opportunities, and potential changes and developments in the highly competitive LiDAR technology and related industries. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the definitive proxy statement/prospectus filed with the SEC on March 11, 2021 and other documents filed by Innoviz from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Innoviz assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Innoviz gives no assurance that it will achieve its expectations.

Contact Information

[email protected]

Investor Contact

Maya Lustig

Innoviz Technologies
+972 54 677 8100
[email protected] 

Gateway Investor Relations
Cody Slach or Matt Glover
(949) 574-3860
[email protected]

SOURCE Innoviz Technologies

DUBLIN, April 7, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa (“nemvaleukin”, formerly referred to as ALKS 4230), Alkermes’ novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSD’s KEYTRUDA^® (pembrolizumab), in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer. Under the terms of the agreement, Alkermes is responsible for conducting the phase 3 study, which is planned to initiate in the second half of 2021.

“We are pleased to collaborate with MSD to evaluate nemvaleukin in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer, a patient population for which there are limited treatment options available and overall survival remains low. Importantly, there are no anti-PD-1 treatments currently approved for this tumor type,” said Jessicca Rege, Ph.D., Vice President, Head of Oncology at Alkermes. “Nemvaleukin in combination with KEYTRUDA has demonstrated antitumor activity in heavily pre-treated patients with platinum-resistant ovarian cancer in the ongoing ARTISTRY-1 study, with durable and deepening responses observed. We look forward to initiating this phase 3 study to further evaluate the potential clinical utility of this combination in this tumor type and advancing our interactions with regulatory authorities related to potential registration strategies for the combination in platinum-resistant ovarian cancer.”

About nemvaleukin alfa

Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven antitumor effects of existing IL-2 therapy while mitigating certain limitations.

About the ARTISTRY Clinical Development Program
 
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin in patients with advanced solid tumors.

ARTISTRY-1 and ARTISTRY-2 are phase 1/2 studies evaluating the safety, tolerability, efficacy and pharmacokinetic and pharmacodynamic effects of nemvaleukin in patients with refractory advanced solid tumors, in both monotherapy and combination settings with the PD-1 inhibitor pembrolizumab (KEYTRUDA^®). In ARTISTRY-1, nemvaleukin is administered as an intravenous infusion daily for five consecutive days, followed by an off-treatment period. In the ongoing phase 2 efficacy expansion stage of ARTISTRY-2, nemvaleukin is administered subcutaneously once every seven days.

ARTISTRY-3 is a phase 2 study evaluating the clinical and immunologic effects of intravenous nemvaleukin monotherapy on the tumor microenvironment of a variety of advanced, malignant solid tumors.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the potential therapeutic value of nemvaleukin alfa (“nemvaleukin”, formerly referred to as ALKS 4230) as a cancer immunotherapy when used in combination with KEYTRUDA for the treatment of patients with platinum-resistant ovarian cancer (PROC); plans for initiating a phase 3 study in the second half of 2021; and plans to advance interactions with regulatory authorities related to potential registration strategies for the combination in platinum-resistant ovarian cancer. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others, whether nemvaleukin, as a monotherapy or in combination, could be shown to be unsafe or ineffective; whether preclinical results and data from ongoing clinical studies for nemvaleukin will be predictive of future or final results from such studies, results of future clinical studies or real-world results; whether future clinical trials or future stages of ongoing clinical trials for nemvaleukin will be initiated or completed on time or at all; changes in the cost, scope and duration of, and clinical trial operations for, development activities for nemvaleukin, including changes relating to the impact of the novel coronavirus (COVID-19) pandemic; and those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2020 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Sourojit Bhowmick, Ph.D. +1 781 609 6397

View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-announces-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-nemvaleukin-alfa-in-combination-with-keytruda-in-patients-with-platinum-resistant-ovarian-cancer-301263617.html

SOURCE Alkermes plc

Technology suite includes innovative credit cards, an end-to-end digital platform, cards issuance and adjudication, and the world’s largest embedded loyalty and rewards

TORONTO, April 7, 2021 /PRNewswire/ — Brim Financial (Brim), a Canadian next-generation Fintech company and certified credit card issuer, today announced a partnership with Canadian Western Bank (CWB) to roll out Brim’s Platform as a Service (PaaS) and credit card infrastructure. Brim’s PaaS enables CWB to offer a full suite of personal credit cards and an integrated digital banking platform with best-in-class globally open loyalty, delivering a robust value proposition that helps ensure CWB continues to exceed its customers’ expectations.

Rasha Katabi, CEO and Founder of Brim Financial said, “We are excited to partner with CWB, enabling the seamless integration of our cutting-edge financial products and platform within the CWB ecosystem.  We’re focused on powering the growth of our partners, and our partnership with CWB’s established business, paired with our state-of-the-art infrastructure and technology is a win-win. Together we are redefining banking services in Canada. We’re responding to a heightened need for digital delivery, convenience, simplicity and uniquely differentiated customer experiences.”

In addition to its innovative suite of credit card products, Brim’s PaaS offers omni-channel digital experiences including an in-branch onboarding portal and an online self-service portal which will be integrated within CWB’s existing banking platform and access Brim’s proprietary rewards technology and global partner network. CWB will lean on Brim’s infrastructure and end-to-end modular solution including card issuance and adjudication, customer support, platform design and development, loyalty management, banking centre employee tools and portal, compliance and risk management, analytics and more.

“Our partnership with Brim to roll out a suite of consumer credit cards and innovative platform is another step forward in how CWB continues to deliver a boutique offering designed for business owners that seamlessly integrates personal banking needs into a business and wealth financial relationship,” says Stephen Murphy, Executive Vice President, Banking. “Brim’s vision to combine banking, loyalty and e-commerce into a single platform aligns with our reputation for providing a premium client experience. We have a common ambition to disrupt Canadian financial services and provide a clear alternative to those who want more from their financial partner.”

With Brim, CWB clients are empowered with digital first products and services that offer an unprecedented, flexible, secure and rewarding customer experience:

• Unlimited earning potential with Brim Rewards
• Embedded Buy-Now, Pay-Later capabilities
• Mobile Wallet compatibility, including Apple Pay, Google Pay, Fitbit and others
• Budget and Spend Monitoring
• Real-Time Lock Card, plus Block/Unblock Foreign or Online Transactions
• Family Cards enabling full visibility and control over each authorized users’ card
• Free Global Wi-Fi and more

About Brim Financial

Brim powers banking and integrated e-commerce on a single platform. Brim brings ground-breaking innovation to the fintech space with a full product suite of consumer and business credit cards, consumer digital banking services, a globally open rewards and loyalty ecosystem, and financial products including Buy-Now, Pay-Later capabilities seamlessly integrated into all business and consumer revolving credit card products. They have continued to grow their presence, rolling out a comprehensive B2B2C strategy, partnering with FIs, Fintechs and large corporations to enable end-to-end digital banking platforms. Brim enables B2B partners to launch a turnkey, digital-first financial platform and product suite with embedded open loyalty that revolutionizes the value proposition for consumers and businesses. In addition, Brim’s embedded finance tech stack enables merchants to be live on the Brim ecosystem in real-time without any need for Point-Of-Sale (POS) integration. Brim’s smart Open Rewards/Loyalty infrastructure is live at all merchants worldwide. Brim is headquartered in Toronto, Canada. To learn more, visit brimfinancial.com

About CWB

Canadian Western Bank (TSX:CWB.TO) is a chartered, full-service bank that offers business and personal banking solutions and expertise, along with an unwavering obsession with our clients’ success. We’ve offered customized financial solutions for over 35 years, and operate with a clear focus on meeting the unique financial needs of business owners. Through our network of branches, business offices and mobile relationship teams, we help clients grow their businesses, manage their money and realize their financial potential. Learn more at www.cwbank.com.

View original content:http://www.prnewswire.com/news-releases/brim-announces-partnership-with-canadian-western-bank-to-launch-platform-as-a-service-paas-301263464.html

SOURCE Brim Financial

On-Demand Classes Curated By Community of Fitness Trainers – 



Exercises Optimized for Resistance Band Training

Key Highlights:

• TUT Training
  ^TM
  Mobile app, powered by industry leader Trainerize, serves as a platform for consumers and fitness trainers to develop and promote on-demand classes to their followers
• Trainers can develop exercises that incorporate novel resistance-band technology used in the TUT Rower
  ^TM
  and TUT Trainer™ personal gym equipment
• App seamlessly integrates with Apple Watch/Healthkit, Fitbit, Withings, My Fitness Pal
• Launches with 250 exercises and 30 days of on-demand classes developed by the fitness community to optimize resistance band ‘Time Under Tension’ training–a totally new way of working out at home

VANCOUVER, BC, April 7, 2021 /PRNewswire/ – AAJ Capital 2 Corp. (TSXV: AAJC.P) (“AAJ“) is pleased to announce that TUT Fitness Group Limited (“TUT“) has launched the TUT Training™ app, available today, via Apple App Store and Google Play, to all TUT customers.

The TUT Training^TM app, powered by fitness training software leader Trainerize, is a platform for fitness trainers to offer on-demand training videos to consumers,  leveraging TUT’s portable patented resistance band technology to create a new way of working out. The TUT Training app launches with 250 exercise videos and a free introductory 30-day exercise regimen developed by world-class performance coaches. The TUT Training^TM app integrates seamlessly with existing fitness monitoring devices including Fitbit, Withings, My Fitness Pal, and Apple Healthkit. The app offers both freemium and paid subscription tiers.

TUT has invented a novel, portable way to incorporate Time Under Tension (the amount of time a muscle is under strain during a repetition), into the global $9.5B¹ home gym equipment market. Using patented, stackable resistance band plates rather than traditional metal weights, the TUT Gym and Rower targets every muscle group generating a higher caloric burn, without the added pressure to joints and tendons. 

“We have ambitious plans to make training from home both easier and more affordable for everyone.  Our mobile training app is a first step to allowing our growing community to make that personal and digital connection to their gym and favourite trainers, through on-demand classes and flexibly priced training content,” said Rob Smith, President of TUT Fitness Group. “It also gives us a chance to introduce the world to our amazing trainer team.”

The company is also pleased to announce that fitness industry executive and TUT Strategic Advisor, Mitch Malandrino, has joined AAJ as Vice President of Corporate Development.  Malandrino commented the following “The TUT Training app is not only a place where you can access all your favourite TUT classes, but also a place where you can track your entire fitness journey. Everything from tracking your body stats, nutrition, to progress photos. You can also connect your wearables such as Apple Watch, Fitbit, and any wearable that connects to Apple Health. The TUT Training app is the perfect match for this lightweight portable gym.”

MEET SOME OF OUR TRAINERS:
Connor Mahannah:  https://tutfitnessgroup.com/tuttrainers-connor/ 
Sammy HodHod: https://tutfitnessgroup.com/tuttrainers-sammy/  
Gigi Neil: https://tutfitnessgroup.com/tuttrainers-gigi/ 
 

FURTHER INFORMATION:

The TUT Training^TM mobile phone app is available via Apple App Store or Google Play to all TUT device customers. The TUT Tower^TMand TUT Rower^TM personal gym equipment are available at official stores:

Canada: https://tuttrainer.ca/
US: https://thetuttrainer.com/

LINKS:

https://www.instagram.com/tuttrainer/

https://www.facebook.com/tuttrainer

https://twitter.com/tuttrainer/ 
https://www.linkedin.com/company/tutfitness/
Highlights Video: TUT Trainer™ – TUT Training App (YouTube)
Installation Video: https://tutfitnessgroup.com/installation/

ABOUT TUT FITNESS GROUP:   
TUT Fitness Group is a private British Columbia based fitness company that has designed, developed and manufactured one of the world’s smallest and most affordable high performance gyms. Incorporated in 2018, TUT is an emerging player in the connected Home Gym and Fit Tech hardware space, targeting the US$9.4B¹ Global Home Exercise Equipment Market with a novel,  portable way to incorporate Time Under Tension (the amount of time a muscle is under strain during a repetition).  The TUT system  utilizes industry-first, patented stackable resistance band based TUT Plates^TM in 2, 5, 10, 20, & 40 lb. increments rather than metal weights,  a breakthrough in strength and cardio training,  that targets every muscle group, and  generates a higher caloric burn,  without the added pressure to joints and tendons.  At a combined 32 lbs., TUT’s flagship products, the TUT Trainer^TM and Rower are more convenient and affordable than other leading home gym and cardio equipment products. The TUT Training^TM app targets the Online Fitness Market, expected to be US$30B² by 2026,  by providing consumers and trainers with a digital connection to on-demand training videos and fitness related training content. The App seamlessly integrates with Apple Watch/Healthkit, Fitbit, Withings, My Fitness Pal. 

ABOUT TRAINERIZE:
Trainerize (trainerize.com) is a client engagement mobile app and software that allows fitness coaches and fitness businesses to expand their reach beyond their physical spaces, better connect with members, build meaningful relationships, and digitize the training experience. Fitness coaches and fitness businesses use Trainerize to boost member engagement through digital services as well as attracting new members by tapping into the market of online training.

For further information please contact:
[email protected] 
Rob Smith
President, TUT Fitness Group

Forward-Looking Statements

Certain statements in this release are forward-looking statements or information, which include completion of the proposed Transaction and related financing, listing of warrants, development of technologies, customer demand for TUT’s products, future plans, regulatory approvals and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, security threats, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the demand for its products, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, failure to obtain regulatory approval, the continued availability of capital and financing, equipment failures, litigation, increase in operating costs, the impact of COVID-19 or other viruses and diseases on the Company’s ability to operate, failure of counterparties to perform their contractual obligations, exchange rate fluctuations, government regulations, loss of key employees and consultants, and general economic, market or business conditions. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information.

There can be no assurance that the proposed Transaction or Concurrent Financing will be completed or, if completed, will be successful.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aaj-capital-2-corp-announces-the-launch-of-tut-fitness-app-to-connect-trainers-with-home-gym-users-301263748.html

SOURCE TUT Fitness Group Limited